Po­sei­da shares in­cre­men­tal Phase 1 up­date for Roche-part­nered off-the-shelf CAR-T

Po­sei­da Ther­a­peu­tics said that 21 of 23 pa­tients (91%) re­spond­ed to the al­lo­gene­ic CAR-T ther­a­py it’s de­vel­op­ing with Roche when giv­en a high­er dose of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER